SCHEMBL4679976

SCHEMBL4679976

O=C(C=C(O)c1nn[nH]n1)c1cn(S(=O)(=O)c2ccc(F)cc2)cc1CCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.37
NCEH1 Q6PIU2 1/20 0.37
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
PKM P14618 2/20 0.33
PTGDR2 Q9Y5Y4 3/20 0.33
CYP2C8 P10632 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
PTGS2 P35354 2/20 0.33
SLC16A3 O15427 1/20 0.33
LMNA P02545 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
GRM4 Q14833 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672992 0.91 CES1 (0.37) CES1NCEH1ALDH1A1GAAMEN1
SCHEMBL4671894 0.88 LMNA (0.33) PTGDR2CYP2C8CYP2C19LMNAGRM4
SCHEMBL4676571 0.86 SGMS1 (0.35) ALDH1A1GAAMEN1HPGDKMT2A
SCHEMBL4679350 0.83 CES1 (0.39) CES1NCEH1
SCHEMBL4673793 0.81 CES1 (0.38) CES1NCEH1ALDH1A1GAAMEN1
SCHEMBL4676460 0.78 CES1 (0.43) CES1NCEH1
SCHEMBL4675686 0.78 CES1 (0.38) CES1NCEH1ALDH1A1PTGDR2LMNA
SCHEMBL4673837 0.78 CES1 (0.39) CES1NCEH1ALDH1A1LMNATAAR1
SCHEMBL4675163 0.77 SGMS1 (0.35) ALDH1A1GAAMEN1KMT2APKM
SCHEMBL4672120 0.77 PKM (0.39) ALDH1A1KMT2APKMPTGDR2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.